ID   UKF-NB-3rDOX20
AC   CVCL_RS04
DR   Wikidata; Q54990339
RX   PubMed=16142320;
RX   PubMed=19147553;
RX   PubMed=22170099;
RX   PubMed=27517323;
WW   https://www.wass-michaelislab.org/rccl.php
CC   Part of: Resistant Cancer Cell Line (RCCL) collection.
CC   Doubling time: 18 +- 1.9 hours (PubMed=16142320).
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_9904 ! UKF-NB-3
SX   Female
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 29-06-23; Version: 7
//
RX   PubMed=16142320; DOI=10.3892/ijo.27.4.1029;
RA   Kotchetkov R., Hernaiz Driever P., Cinatl J., Michaelis M.,
RA   Karaskova J., Blaheta R.A., Squire J.A., von Deimling A., Moog J.,
RA   Cinatl J. Jr.;
RT   "Increased malignant behavior in neuroblastoma cells with acquired
RT   multi-drug resistance does not depend on P-gp expression.";
RL   Int. J. Oncol. 27:1029-1037(2005).
//
RX   PubMed=19147553; DOI=10.1158/0008-5472.CAN-08-1856;
RA   Michaelis M., Rothweiler F., Klassert D., von Deimling A., Weber K.,
RA   Fehse B., Kammerer B., Doerr H.-W., Cinatl J. Jr.;
RT   "Reversal of P-glycoprotein-mediated multidrug resistance by the
RT   murine double minute 2 antagonist nutlin-3.";
RL   Cancer Res. 69:416-421(2009).
//
RX   PubMed=22170099; DOI=10.1038/cddis.2011.129;
RA   Michaelis M., Rothweiler F., Barth S., Cinatl J., van Rikxoort M.,
RA   Loschmann N., Voges Y., Breitling R., von Deimling A., Rodel F.,
RA   Weber K., Fehse B., Mack E., Stiewe T., Doerr H.-W., Speidel D.,
RA   Cinatl J. Jr.;
RT   "Adaptation of cancer cells from different entities to the MDM2
RT   inhibitor nutlin-3 results in the emergence of p53-mutated
RT   multi-drug-resistant cancer cells.";
RL   Cell Death Dis. 2:e243.1-e243.8(2011).
//
RX   PubMed=27517323; DOI=10.18632/oncotarget.11160;
RA   Loschmann N., Michaelis M., Rothweiler F., Voges Y., Balonova B.,
RA   Blight B.A., Cinatl J. Jr.;
RT   "ABCB1 as predominant resistance mechanism in cells with acquired
RT   SNS-032 resistance.";
RL   Oncotarget 7:58051-58064(2016).
//